Results 111 to 120 of about 2,177,587 (253)

Biotechnological Potential of Sargassum ilicifolium Seaweed: A Proximate Composition of Antibacterial, Antioxidant, and Hypoglycemic Bioactive Compounds

open access: yesBioResources
Seaweed has gained significant attention due to its extensive use in nutraceuticals and pharmaceuticals. Therefore, this study was conducted to perform proximate analysis, screen and quantify phytochemicals, and analyze the pharmacological potential of ...
Abdulaziz S. Fakhouri
doaj  

Identification of enzyme inhibitors using therapeutic target protein-magnetic nanoparticle conjugates

open access: yes, 2012
Target protein-magnetic nanoparticle (MNP) conjugates, i.e. alpha-glucosidase-MNP and protein tyrosine phosphatase 1B (PTP1B)-MNP, were prepared and evaluated for the first time for affinity extraction of enzyme inhibitors from herbal extracts.
Xue, Ying   +6 more
core  

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

open access: yesMolecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington   +10 more
wiley   +1 more source

Molecularly imprinted microgels as enzyme inhibitors

open access: yes, 2009
International audienceWe demonstrate, on the example of trypsin, the use of water-soluble molecularly imprinted polymer microgels as specific enzyme inhibitors.
Schembri, Carol   +3 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Palatability of crushed ß-blockers, converting enzyme inhibitors and thiazides

open access: yes, 2012
WHAT IS KNOWN AND OBJECTIVES: A problem that often affects antihypertensive drugs is the lack of formulations appropriate for childhood. Parents, therefore, crush tablets and administer the antihypertensive drug mixed with solid food or a palatable drink.
Fossali, E F   +15 more
core   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

open access: yesMolecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic   +15 more
wiley   +1 more source

The effects of ovarian enzyme modulators on folliculogenesis and cyst development in the porcine ovary. [PDF]

open access: yes, 2007
The first aim of the research conducted as part of this thesis was to investigate the expression and activities of 110HSD enzymes in porcine mural granulosa cells and COCs from small, medium and large antral follicles, as well as from ovarian cysts. Both
Sunak, N.
core  

Molecularly Imprinted Microgels as Enzyme Inhibitors

open access: yes, 2016
We demonstrate, on the example of trypsin, the use of water-soluble molecularly imprinted polymer microgels as specific enzyme inhibitors. Using a strong anchoring monomer, methacryloylaminobenzamidine, the growing polymer chains are confined to close ...
Carol Schembri (2343310)   +3 more
core   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

open access: yesMolecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy